Stay updated on Fruquintinib & Tislelizumab in Solid Tumors Clinical Trial
Sign up to get notified when there's something new on the Fruquintinib & Tislelizumab in Solid Tumors Clinical Trial page.

Latest updates to the Fruquintinib & Tislelizumab in Solid Tumors Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoChange DetectedRevision tag updated from v3.6.2 to v3.6.3 on the page, indicating a newer build of the Study Details page. The update does not change the study content or user-facing information.SummaryDifference0.0%

- Check18 days agoChange DetectedRevision updated from v3.6.0 to v3.6.2, indicating a page/template update. No study content, eligibility criteria, or results appear to be affected.SummaryDifference0.0%

- Check32 days agoChange DetectedThe page now shows that no participants are being recruited and adds user-focused sections such as How to Read a Study Record, Common Questions, and How to Join a Study, while updating the Intervention/Treatment heading formatting.SummaryDifference0.4%

- Check39 days agoChange DetectedRevision label at the bottom of the page changed from v3.5.4 to v3.5.5, reflecting a small update to the page.SummaryDifference0.0%

- Check61 days agoChange DetectedRevision: v3.5.4 is now listed, replacing the previous v3.5.3, indicating a new version of the related document or protocol.SummaryDifference0.0%

- Check83 days agoChange DetectedThe page revision/version indicator was updated from v3.5.2 to v3.5.3.SummaryDifference0.0%

Stay in the know with updates to Fruquintinib & Tislelizumab in Solid Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Fruquintinib & Tislelizumab in Solid Tumors Clinical Trial page.